Double‐blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease

@article{Bronzova2010DoubleblindSO,
  title={Double‐blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease},
  author={Juliana Bronzova and Cristina Sampaio and Robert A. Hauser and Anthony E. Lang and Olivier Rascol and Ad Theeuwes and Serge V van de Witte and Guus van Scharrenburg},
  journal={Movement Disorders},
  year={2010},
  volume={25}
}
This study examined the efficacy and safety of the partial dopamine agonist, pardoprunox (SLV308), in the treatment of patients with early Parkinson's disease (PD). Patients were randomized to receive pardoprunox (n = 69) or placebo (n = 70). Pardoprunox was titrated to each patient's optimal dose (9–45 mg/d) over 2 to 6 weeks and then maintained at this dose for a further 3 weeks. Concomitant anti‐Parkinson treatment was not permitted. In the primary analysis, Unified PD Rating Scale (UPDRS… 
Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials
TLDR
Pardoprunox significantly improved motor symptoms in patients with early Parkinson's disease, but further investigation into the dose and titration schedule is required to improve tolerability.
Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease
TLDR
Targets of continuous dopaminergic stimulation seem the most promising to prevent or ameliorate LID, and the success of future therapeutic strategies once moderate to severe LID occur will depend on the translation from preclinical experimental models into clinical practice in a bidirectional process.
Dopamine receptor agonists for Parkinson's disease
TLDR
This review summarizes pre-clinical and clinical data on second-generation, first-line non-ergolinic DA agonists and their motor, non-motor and putative neuroprotective effects and addressed the anti-parkinsonian potential of recently developedDA agonists that reached Phase II and III clinical trials.
Therapies for dopaminergic‐induced dyskinesias in parkinson disease
TLDR
These findings support the hypothesis of glutamate overactivity in the development of dyskinesias and suggest more continuous delivery of dopaminergic medication, such as through intraintestinal or subcutaneous routes, is promising but invasive and associated with injection site reactions.
Dyskinesia in Parkinson's Disease Therapy
TLDR
This Special Issue discusses recent breakthroughs in this direction and provides an update of the clinical features and management of L-DOPA-induced dyskinesia, and describes the management of this condition, based on the use of various types of dopaminergic agonists.
Managing the patient with newly diagnosed Parkinson disease
TLDR
The treatment of early Parkinson disease is generally symptomatic, although therapy that also offers neuroprotection in early-stage PD would be welcomed, and neuro protective strategies under study include enhancement of mitochondrial function, antiinflammatory mechanisms, calcium channel blockade, and uric acid elevation.
...
1
2
3
4
...

References

SHOWING 1-10 OF 45 REFERENCES
Ropinirole for the treatment of early Parkinson's disease
TLDR
Ropinirole monotherapy is an effective and well-tolerated therapeutic option for treatment of early Parkinson's disease and was a significantly greater percentage improvement in UPDRS motor score than patients who received placebo.
Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study
TLDR
Piribedil is effective and safe as early PD therapy as well as consistent with that reported for other dopamine agonists, gastrointestinal side effects being the most common.
Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
TLDR
Initial pramipexole treatment resulted in significantly less development of wearing off, dyskinesias, or on-off motor fluctuations compared with levodopa (51%) (hazard ratio, 0.45; 95% confidence interval [CI], 0.66), and the mean improvement in total UPDRS score from baseline to 23.5 months was greater in thelevodopa group than in the pramipingxole group (9.5 points; P<.001).
Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease.
TLDR
The rotigotine transdermal system consistently demonstrated statistically significant and clinically relevant efficacy over placebo in patients with early Parkinson disease and was well tolerated.
Antagonist effect of terguride in Parkinson's disease.
TLDR
Results show dopamine antagonist activity of terguride in patients with Parkinson's disease treated with Levodopa, and further studies using a wider dose titration are required to evaluate the possible role of dopamine partial agonists in the therapy of levodopa-induced dyskinesias.
Pharmacology of dopamine agonists in the treatment of Parkinson’s disease
TLDR
Continuous administration of long-acting dopamine agonists may reverse the priming process initiated by l-dopa, markedly decreasing dyskinesia intensity with a minimal loss of antiparkinsonian activity, at least in MPTP-treated primates.
Effects of serotonin 5‐HT1A agonist in advanced Parkinson's disease
TLDR
It is suggested that 5‐HT1A receptor stimulation in levodopa‐treated parkinsonian patients can modulate striatal dopaminergic function and that 5-HT2A agonists may be useful as levodOPA adjuvants in the treatment of PD.
Continuous dopamine-receptor stimulation in early Parkinson's disease
Motor effects of the partial dopamine agonist (−)‐3‐(3‐hydroxyphenyl)‐N‐n‐propylpiperidine (preclamol) in Parkinson's disease
  • L. Metman, V. Sethy, T. Chase
  • Psychology, Medicine
    Movement disorders : official journal of the Movement Disorder Society
  • 1994
TLDR
The results suggest that partial dopamine agonists can exert agonist or antagonist activity in parkinsonian patients depending on concurrent dopaminergic tone and that this class of agents may have relatively limited clinical utility.
Preventing and controlling dyskinesia in Parkinson's disease—A view of current knowledge and future opportunities
  • P. Jenner
  • Psychology, Biology
    Movement disorders : official journal of the Movement Disorder Society
  • 2008
TLDR
CDS does explain some important features of dyskinesia induction in PD but it may not apply to early PD when remaining dopaminergic neurones buffer against pulsatile stimulation and it appears that it is CDD which is more important in regulating therapeutic efficacy.
...
1
2
3
4
5
...